Literature DB >> 6388495

The disease spectrum, epidemiology, and etiology of toxic-shock syndrome.

P J Chesney, M S Bergdoll, J P Davis, J M Vergeront.   

Abstract

From this composite picture of the history and recent developments related to TSS, several points are clear. TSS is not a new disease, and TST-producing strains of S. aureus are not new. What is new is the recent dramatic increase of this disease in young women who use tampons during menses and who lack antibody to TST. What is also new is the recognition that the disease commonly recurs but only in menstrually associated cases. What remains to be determined are the precise role of tampons, the factors leading to toxin induction, and the mechanism of action of this potent toxin. In order to better determine what these factors and mechanism of action are, and to determine if the TST marker protein is in fact the critical toxin, a reliable animal model is badly needed. Finally, a reliable laboratory test to confirm the clinical diagnosis is another high-priority need. The further unraveling of the secrets of this complex disease may greatly enhance our understanding of the disease associated with this toxin, of the intricacies of toxin production by other bacteria, and of the role that exogenous cofactors play in disease processes.

Entities:  

Mesh:

Year:  1984        PMID: 6388495     DOI: 10.1146/annurev.mi.38.100184.001531

Source DB:  PubMed          Journal:  Annu Rev Microbiol        ISSN: 0066-4227            Impact factor:   15.500


  13 in total

1.  Imbalanced serum IgG subclass pattern in toxic shock syndrome patients: deficiency of specific IgG1 and IgG4 subclass antibodies to toxic shock syndrome toxin 1.

Authors:  B Christensson; P J Johansson; V A Oxelius
Journal:  Clin Exp Immunol       Date:  1986-11       Impact factor: 4.330

2.  Increased incidence of menstruation-associated bactericidal defects in neutrophils from women who have recovered from toxic shock syndrome.

Authors:  E M Berger; J E Lockey; V H Aldrich; J E Repine
Journal:  Inflammation       Date:  1986-12       Impact factor: 4.092

3.  Association of toxic shock toxin-1 determinant with a heterologous insertion at multiple loci in the Staphylococcus aureus chromosome.

Authors:  M C Chu; B N Kreiswirth; P A Pattee; R P Novick; M E Melish; J F James
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

4.  Variable effect of toxic shock toxins from different sources on neutrophil function in vitro.

Authors:  E M Berger; G A Shibao; S N Brown; J E Repine
Journal:  Inflammation       Date:  1988-10       Impact factor: 4.092

5.  Glycerol monolaurate inhibits the production of beta-lactamase, toxic shock toxin-1, and other staphylococcal exoproteins by interfering with signal transduction.

Authors:  S J Projan; S Brown-Skrobot; P M Schlievert; F Vandenesch; R P Novick
Journal:  J Bacteriol       Date:  1994-07       Impact factor: 3.490

Review 6.  Syndromes with renal failure and shock.

Authors:  M Levin
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

7.  Immunohistological localisation of staphylococcal toxic shock syndrome toxin (TSST-1) antigen in sudden infant death syndrome.

Authors:  M J Newbould; J Malam; J M McIllmurray; J A Morris; D R Telford; A J Barson
Journal:  J Clin Pathol       Date:  1989-09       Impact factor: 3.411

8.  Enterotoxins and toxic-shock syndrome toxin-1 in non-enteric staphylococcal disease.

Authors:  R R Marples; A A Wieneke
Journal:  Epidemiol Infect       Date:  1993-06       Impact factor: 2.451

9.  One in five mortality in non-menstrual toxic shock syndrome versus no mortality in menstrual cases in a balanced French series of 55 cases.

Authors:  E Descloux; T Perpoint; T Ferry; G Lina; M Bes; F Vandenesch; I Mohammedi; J Etienne
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01       Impact factor: 3.267

10.  Role of surface proteins in staphylococcal adherence to fibers in vitro.

Authors:  A L Cheung; V A Fischetti
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.